Core Insights - Medical Care Technologies, Inc. has adopted a new corporate logo in preparation for the launch of its first consumer-based AI mobile application, Snapshot Recipes [1] - The new logo signifies the company's expanding focus on AI-driven mobile applications within the lifestyle, wellness, and medical pre-screening technology sectors [1] Company Developments - The launch of Snapshot Recipes marks a significant step for the company as it ventures into consumer-based applications [1] - The adoption of a new logo reflects the company's strategic shift towards integrating artificial intelligence into its product offerings [1]

BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY. Please contact your Citi representative to request a meeting at the conference. About BrainsWayBrainsWay is a global le ...

Core Insights - The healthcare sector, particularly pharmaceutical and medical device companies, showed strong performance in the 2025 earnings season, outperforming the industry average [1][2] - Key companies discussed include Eli Lilly, AstraZeneca, Edwards Lifesciences, and Medtronic, highlighting significant revenue growth drivers [1] Sector Performance - The earnings reports reflect a backdrop of challenges such as geopolitical shifts, pricing pressures, and patent losses affecting the industry [2]

Group 1 - Helix Exploration has become the first helium producer in Montana, with operations scaling up at the Rudyard project and discussions with distributors underway [1] - Atlantic Lithium has decided to withdraw from takeover talks to concentrate on its growth, stating that the offer did not reflect the true value of its Ewoyaa Lithium Project in Ghana [1] Group 2 - AOTI Inc is anticipating a significant breakthrough with an upcoming US reimbursement decision that could be transformative, alongside reporting a 14% increase in 2025 annual revenue to over $66 million [2] - Caledonia Mining has selected Stanbic Bank Zimbabwe and CBZ Bank as lead banks for a new $150 million funding facility aimed at advancing the development of its Bilboes gold project in Zimbabwe [2]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Hangzhou Tangji Medical Technology Co., Ltd. 杭州糖吉醫療科技股份有限公司 (A joint stock company incorporated in the People's Republic of China with limited lia ...

Core Viewpoint - Tandem Diabetes reported better-than-expected financial results, showing improvements in sales and profitability, while also providing guidance for future growth despite a slight miss on sales expectations for fiscal 2026 [2][3][4]. Financial Performance - The company reported a fourth quarter adjusted loss of one cent, compared to the consensus loss of eight cents [2]. - Sales increased by 3% year over year to $290.4 million, surpassing the consensus estimate of $277.03 million [2]. - Adjusted gross profit rose from 51% to 58%, and adjusted operating profit was $8.3 million, a significant improvement from a loss of $30.2 million a year ago [2]. Guidance - For fiscal 2026, Tandem Diabetes forecasts sales between $1.065 billion and $1.085 billion, slightly below the consensus of $1.103 billion [3]. - The company anticipates an adjusted EBITDA margin of approximately 5% to 6% [3]. Management Commentary - The company aims for double-digit pump shipment growth in 2026 and is implementing a pay-as-you-go model in the U.S. to enhance customer access and revenue predictability [4]. - Management is focused on improving margins and profitability to position the company for accelerated sales growth in 2027 and beyond [5]. Market Performance - The stock is currently trading 12.5% above its 20-day simple moving average (SMA) and 15.3% above its 100-day SMA, indicating strong short-term momentum [6]. - Over the past 12 months, shares have increased by 34.4% and are closer to their 52-week highs [6]. Technical Analysis - The Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the MACD is at 0.15, below its signal line at 0.22, suggesting bearish pressure [6][7]. Analyst Consensus - The stock carries a Buy Rating with an average price target of $25.17, and shares were up 37.53% at $25.47 at the time of publication [8]. - Recent analyst actions include upgrades and target raises from various firms, with key resistance at $35 and support at $20 [9].

Core Insights - The article highlights the launch of DeepRare, the world's first intelligent rare disease diagnostic system developed by a joint team from Shanghai Jiao Tong University and Xinhua Hospital, addressing the global challenge of difficult diagnosis and high misdiagnosis rates in rare diseases [1][4]. Group 1: System Overview - DeepRare employs an innovative "central-body" architecture, surpassing traditional medical AI by breaking data silos and integrating vast amounts of medical literature and clinical cases for deep knowledge internalization [4]. - The system abandons traditional AI's pattern matching, utilizing a human-like "slow thinking" capability through "hypothesis-verification-self-reflection" to analyze diagnostic clues [4]. - DeepRare provides full-process evidence-based "white-box reasoning," ensuring that each diagnostic conclusion is accompanied by a complete traceable evidence chain, addressing the trust crisis in AI healthcare [4]. Group 2: Performance Metrics - Clinical data validation shows that DeepRare's pure phenotype diagnostic accuracy reached 57.18%, an improvement of 23.79 percentage points over the best international models, changing the paradigm that "without genetic testing, diagnosis is difficult" [4]. - The system's diagnostic recall rate surpasses that of rare disease specialists with ten years of clinical experience [4]. - After incorporating genetic sequencing data, the comprehensive first-diagnosis accuracy for complex cases exceeded 70.61%, significantly outperforming commonly used international tools [4]. - The inference reports generated by the system achieved a 95.40% satisfaction rate among doctors, ensuring that diagnoses are "well-founded" [4].

Core Insights - Artificial intelligence, particularly generative AI, is significantly transforming the MedTech industry, with companies like Tempus AI, Inc. leading the way in AI-driven healthcare solutions [1] Product Developments - Tempus launched its HRD-RNA algorithm in February 2026, a next-generation AI model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors [2] - In January 2026, Tempus introduced Paige Predict, an AI-powered digital pathology application that analyzes whole slide images to assist in testing decisions [3] - Tempus received FDA clearance in July 2025 for its ECG-Low EF software, which uses AI to identify patients with low left ventricular ejection fraction [3] - The company also launched Notetaker in May 2025, an AI clinical assistant that records patient sessions to generate clinical notes for electronic health records [3] Industry Collaborations - GE HealthCare is collaborating with NVIDIA to utilize AI and high-performance computing to enhance patient comfort and reduce radiologist burnout [4] - Stryker's Mako SmartRobotics platform integrates AI to improve surgical accuracy in knee and hip procedures, with significant adoption and a recurring revenue model [5] Financial Performance - Tempus' stock has decreased by 21.9% over the past year, while the industry has seen a decline of 37.8%, contrasting with a 14.8% increase in the S&P 500 [6] - The company's current forward Price-to-Sales ratio is 6.63X, higher than the industry average of 5.66X, indicating an expensive valuation [9] Earnings Estimates - Tempus' loss per share estimates for 2025 have remained stable over the past 30 days, with projections of -0.59 for the current year and -0.21 for the next year [10][11]

Core Viewpoint - STRATA Skin Sciences, Inc. has filed a Form 25 with the SEC to deregister its common stock and has suspended trading on Nasdaq, indicating a strategic shift to "go dark" and reduce compliance costs [1][2]. Group 1: Company Actions - The company plans to file a Form 15 around March 2, 2026, to terminate the registration of its common stock and suspend reporting obligations under the Exchange Act [1]. - The delisting from Nasdaq is expected to save significant time and money in general and administrative expenses, allowing the company to focus on its operating plan and customer needs [2]. Group 2: Financial Position - STRATA finished the 2025 fiscal year with a strong balance sheet, including $8 million in cash, indicating financial stability [3]. - The company is engaging with its lender to adjust loan terms to reflect its new status as a private company, with management confident in a favorable outcome [3]. Group 3: Strategic Focus - The decision to "go dark" is aimed at minimizing management distractions related to compliance, allowing for a greater focus on long-term value creation and market expansion [2][3]. - The company anticipates leveraging changes in CPT codes to enhance its market position for XTRAC® excimer laser and TheraclearX® users, which could drive future growth [3].

Core Insights - The NHS-Galleri trial demonstrated a significant reduction in Stage IV cancer diagnoses and an increase in the detection of Stage I and II cancers, although the primary endpoint of statistically significant reduction in Stage III-IV cancers was not met [1][2] Group 1: Trial Results - The Galleri test led to a substantial reduction in cancers detected through emergency presentations, which are linked to higher mortality and healthcare costs [1] - There was a notable increase in the absolute number of Stage I-II cancers among 12 pre-specified deadly cancer types in the intervention group [1] - The overall cancer detection rate improved four-fold when Galleri was added to standard care screening compared to standard care alone for breast, colorectal, cervical, and high-risk lung cancers [1] - A clinically meaningful reduction in Stage IV diagnoses was observed, with over a 20% decrease in the second and third rounds of sequential screening for the specified group of cancers [1][2] Group 2: Trial Design and Objectives - The NHS-Galleri trial is the largest randomized controlled trial assessing a multi-cancer early detection test, involving over 142,000 participants aged 50 to 77 [2] - The primary objective was to show a reduction in late-stage (III-IV) cancers in those receiving the Galleri test compared to those who did not [2] - Secondary objectives included evaluating the performance of the Galleri test, safety, and healthcare resource utilization [2] Group 3: Company and Product Information - GRAIL, Inc. focuses on early cancer detection using next-generation sequencing and machine learning to identify multiple cancer types at earlier stages [2] - The Galleri test can detect over 50 types of cancer through a simple blood draw, significantly increasing the number of cancers detected when used alongside standard screenings [2] - The test is recommended for adults aged 50 or older with an elevated risk for cancer and has the lowest false positive rate among multi-cancer early detection tests [2]